ERBB2 and breast cancer: This concept is supported by Perez26 who showed that advanced BC patients with HER2‐positive tumors exhibit a significantly increased frequency of circulating Tregs, and therapeutic intervention with trastuzumab leads to an overall reduction to normal levels in the frequency of Tregs.